WO2006001278A1 - Ampk活性化剤 - Google Patents
Ampk活性化剤 Download PDFInfo
- Publication number
- WO2006001278A1 WO2006001278A1 PCT/JP2005/011371 JP2005011371W WO2006001278A1 WO 2006001278 A1 WO2006001278 A1 WO 2006001278A1 JP 2005011371 W JP2005011371 W JP 2005011371W WO 2006001278 A1 WO2006001278 A1 WO 2006001278A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- resveratrol
- active ingredient
- ampk
- exercise
- administering
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- Non-Patent Document 3 Nature, Vol. 423, pp762-769, 2003
- resveratrol of the present invention has an excellent effect of suppressing liver enlargement.
- resveratrol suppressed liver hypertrophy due to intake of a high-fat diet, suggesting that it is effective in suppressing fatty liver associated with obesity.
- Example 4 Effect of activating lipid metabolism
- Table 6 shows the measurement results.
- the control lipolytic activity was taken as 100 and expressed as a relative value.
- Ingestion of resveratrol significantly increased the lipolytic activity (3 oxidation activity) of liver and skeletal muscle (liver: P ⁇ 0.001, muscle: p ⁇ 0.001). Therefore, resveratrol was found to be effective in the activity of lipid metabolism.
- composition (1 tablet 250mg) was tableted to produce tablets.
- Example 7 Tablets for prevention and improvement of lifestyle-related diseases
- composition was mixed to produce a tea beverage.
- a carbonated beverage having the following composition was produced.
- a carbonated beverage having the following composition was produced.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/629,486 US20070244202A1 (en) | 2004-06-28 | 2005-06-21 | Ampk Activator |
EP05753416A EP1762234A4 (en) | 2004-06-28 | 2005-06-21 | AMPK AKTIVATOR |
US13/226,016 US20110319497A1 (en) | 2004-06-28 | 2011-09-06 | Ampk activator |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004189150 | 2004-06-28 | ||
JP2004-189150 | 2004-06-28 | ||
JP2005-059874 | 2005-03-04 | ||
JP2005059874 | 2005-03-04 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/226,016 Division US20110319497A1 (en) | 2004-06-28 | 2011-09-06 | Ampk activator |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006001278A1 true WO2006001278A1 (ja) | 2006-01-05 |
Family
ID=35781749
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/011371 WO2006001278A1 (ja) | 2004-06-28 | 2005-06-21 | Ampk活性化剤 |
Country Status (3)
Country | Link |
---|---|
US (2) | US20070244202A1 (ja) |
EP (1) | EP1762234A4 (ja) |
WO (1) | WO2006001278A1 (ja) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009077696A (ja) * | 2007-09-06 | 2009-04-16 | Fujifilm Corp | サラシア属植物の抽出物とフラボノイドを含有する食品 |
JP2009533331A (ja) * | 2006-03-31 | 2009-09-17 | ディーエスエム アイピー アセッツ ビー.ブイ. | 身体的外観を改善するための化合物および化合物の組み合わせの新規の使用 |
JP2011132151A (ja) * | 2009-12-22 | 2011-07-07 | Kirin Holdings Co Ltd | 脂質代謝改善用組成物 |
WO2012072670A2 (en) | 2010-12-03 | 2012-06-07 | L'oreal | Use of a slimming combination |
JP2013027403A (ja) * | 2007-09-06 | 2013-02-07 | Fujifilm Corp | サラシア属植物の抽出物とフラボノイドを含有する食品 |
JP2013224326A (ja) * | 2013-07-24 | 2013-10-31 | Maruzen Pharmaceut Co Ltd | 肥満解消剤、脂肪分解促進剤、サイクリックamp−ホスホジエステラーゼ活性阻害剤、及びラット副睾丸脂肪細胞の脂肪分解促進剤 |
US20140011890A1 (en) * | 2007-01-26 | 2014-01-09 | Washington University | Methods and compositions for treating neuropathies |
JP2014028776A (ja) * | 2012-07-31 | 2014-02-13 | Uha Mikakuto Co Ltd | PGC−1α発現促進剤、抗肥満剤及びメタボリックシンドローム予防・治療剤 |
JP2014101341A (ja) * | 2012-11-22 | 2014-06-05 | Uha Mikakuto Co Ltd | 循環器系疾患の予防・治療に対する新規レスベラトロール2量体の利用 |
JP2014125464A (ja) * | 2012-12-27 | 2014-07-07 | Uha Mikakuto Co Ltd | 循環器系疾患の予防・治療効果を有するヒドロキシスチルベン類・シナピン酸反応生成物 |
JP5571897B2 (ja) * | 2006-02-14 | 2014-08-13 | 株式会社ファンケル | ビタミンcトランスポーター産生促進剤 |
JP2016042813A (ja) * | 2014-08-21 | 2016-04-04 | ポッカサッポロフード&ビバレッジ株式会社 | 非炭酸飲料、及びその製造方法、並びに非炭酸飲料におけるレトロネイザルアロマの組成の変化抑制方法 |
JP2016513734A (ja) * | 2013-03-15 | 2016-05-16 | エーエルエス マウンテン リミテッド ライアビリティ カンパニー | Ampk活性化剤及びセロトニン作動薬を含む医薬組成物並びにそれらの使用方法 |
WO2018002215A1 (en) | 2016-06-30 | 2018-01-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of cardiomyopathies |
WO2020201263A1 (en) | 2019-04-01 | 2020-10-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment and prevention of cardiac remodeling |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070054965A1 (en) * | 2005-09-05 | 2007-03-08 | Kao Corporation | AMPK activating agent |
WO2007041643A1 (en) * | 2005-10-03 | 2007-04-12 | University Of Tennessee Research Foundation | Dietary calcium for reducing the production of reactive oxygen species |
US20080213433A1 (en) * | 2006-06-13 | 2008-09-04 | Frederick Feller | Fluid compositions comprising polyphenols and methods for making and packaging the same |
US20100130597A1 (en) * | 2007-07-06 | 2010-05-27 | The United State Of America, As Represented By The Secretary Of The Dept Of Health And Human Service | Dna-pkcs modulates energy regulation and brain function |
WO2009046964A1 (en) * | 2007-10-10 | 2009-04-16 | Dsm Ip Assets B.V. | Feed composition for companion animals |
AU2007101055A4 (en) * | 2007-10-31 | 2007-12-13 | Norrie, Philip Anthony Dr | Resveratrol Enhanced Wine |
RU2526804C2 (ru) * | 2008-08-06 | 2014-08-27 | Ново Нордиск Хелс Кеа Аг | Конъюгированные белки с пролонгированным действием in vivo |
DE102008037337A1 (de) * | 2008-08-11 | 2010-02-25 | Hermann-Josef Wilhelm | Verfahren zur Herstellung von Wirkstoffen, insbesondere Phenolen aus einer Pflanze |
AU2009307753A1 (en) * | 2008-10-22 | 2010-04-29 | Metaproteomics, Llc | Novel mitochondrial uncoupling methods and compositions for enhancing adipocyte thermogenesis |
US20100112099A1 (en) * | 2008-11-04 | 2010-05-06 | Metaproteomics, Llc | Phytochemical compositions and methods for activating amp-kinase |
US8930490B2 (en) | 2009-01-27 | 2015-01-06 | Apple Inc. | Lifestream annotation method and system |
US20120111936A1 (en) * | 2009-01-27 | 2012-05-10 | Brown Stephen J | Semantic Note Taking System |
US8645383B2 (en) | 2009-01-27 | 2014-02-04 | Stephen J. Brown | Content management system using sources of experience data and modules for quantification and visualization |
EP2520307B1 (en) * | 2009-12-29 | 2015-08-05 | Korea Institute of Oriental Medicine | Composition and functional food using polygonum cuspidatum butanol extract or ethyl acetate extract for treating and preventing obesity |
JP5979762B2 (ja) * | 2010-05-28 | 2016-08-31 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ブドウ葉由来濃縮エキスの製造方法 |
RU2543539C2 (ru) * | 2010-12-20 | 2015-03-10 | Хилл'С Пет Ньютришн, Инк. | Кормовые композиции для домашних животных, вызывающие чувство сытости |
US9005909B2 (en) | 2011-01-06 | 2015-04-14 | Rigel Pharmaceuticals, Inc. | Whole blood assay for measuring AMPK activation |
US20140065099A1 (en) | 2011-02-15 | 2014-03-06 | Ecole Polytechnique Federale De Lausanne (Epfl) | Methods of Treating Mitochondrial Dysfunction |
BR112014000895A2 (pt) | 2011-07-15 | 2019-08-06 | Nusirt Sciences Inc | composições e métodos para modular rotas metabólicas |
US9198454B2 (en) | 2012-03-08 | 2015-12-01 | Nusirt Sciences, Inc. | Compositions, methods, and kits for regulating energy metabolism |
BR112015010947A2 (pt) | 2012-11-13 | 2018-06-05 | Nusirt Sciences Inc | composições e métodos para aumentar o metabolismo energético. |
US9211298B2 (en) * | 2012-11-16 | 2015-12-15 | Song Gao | Compositions containing enriched natural crocin and/or crocetin, and their therapeutic or nutraceutical uses |
MX2015011195A (es) | 2013-03-15 | 2016-03-11 | Nusirt Sciences Inc | La leucina y el acido nicotinico reducen los niveles de lipidos. |
AU2015222754B2 (en) | 2014-02-27 | 2020-06-25 | Nusirt Sciences Inc. | Compositions and methods for the reduction or prevention of hepatic steatosis |
WO2020115765A1 (en) | 2018-12-05 | 2020-06-11 | Celagenex Research (India) Pvt. Ltd. | Novel synergistic composition comprising sirt1 and ampk activators for treating metabolic syndrome |
WO2021246890A1 (en) * | 2020-06-03 | 2021-12-09 | Qatar Foundation For Education, Science And Community Development | Dietary supplement for improved immune health and method of treatment for coronavirus using same |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001072583A (ja) * | 1999-09-07 | 2001-03-21 | Sunstar Inc | 高脂血症の予防又は治療用組成物 |
WO2003009838A1 (fr) * | 2001-07-26 | 2003-02-06 | Institute Of Radiation Medicine, Academy Of Military Medical Sciences, Pla | Utilisation de composes de stilbene dans la preparation de medicaments pour le traitement ou la prevention du diabete et des maladies associees au retrovirus |
WO2003039535A1 (en) * | 2001-10-05 | 2003-05-15 | Interhealth Nutraceuticals, Inc. | Method and composition for preventing or reducing the symptoms of insulin resistance syndrome |
JP2003300904A (ja) * | 2002-04-05 | 2003-10-21 | National Cardiovascular Center | 循環器系障害の進展を抑制する医薬組成物 |
WO2005065667A2 (en) * | 2003-12-29 | 2005-07-21 | President And Fellows Of Harvard College | Compositions for treating or preventing obesity and insulin resistance disorders |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6048903A (en) * | 1994-05-03 | 2000-04-11 | Robert Toppo | Treatment for blood cholesterol with trans-resveratrol |
WO1998012189A1 (en) * | 1996-09-20 | 1998-03-26 | The Howard Foundation | Method of producing polyphenol-containing compositions |
IT1291113B1 (it) * | 1997-03-20 | 1998-12-29 | Sigma Tau Ind Farmaceuti | Composizione nutritiva terapeutica per soggetti affetti da diabete mellito |
US20020068365A1 (en) * | 1998-07-28 | 2002-06-06 | Eric H. Kuhrts | Controlled release nitric oxide producing agents |
EP1161944B1 (en) * | 1999-01-29 | 2006-09-20 | Sunstar Inc. | Drugs, foods and oral compositions containing stilbene-type compounds |
FR2790645B1 (fr) * | 1999-03-12 | 2001-06-08 | Arkopharma Laboratoires | Complement alimentaire et procede de traitement cosmetique a base d' un extrait de raisin riche en polyphenols |
US6573299B1 (en) * | 1999-09-20 | 2003-06-03 | Advanced Medical Instruments | Method and compositions for treatment of the aging eye |
US6812248B2 (en) * | 2000-07-05 | 2004-11-02 | John Hopkins University School Of Medicine | Prevention and treatment of degenerative diseases by glutathione and phase II detoxification enzymes |
JP3735292B2 (ja) * | 2001-07-26 | 2006-01-18 | 三菱重工業株式会社 | ダイエット効果のある健康食品および製剤 |
JP2003252766A (ja) * | 2002-02-28 | 2003-09-10 | Sanei Gen Ffi Inc | シアニジン3−グルコシドを有効成分とする抗肥満及び/又は抗糖尿病剤 |
JP2006273834A (ja) * | 2004-06-28 | 2006-10-12 | Kao Corp | Ampk活性化剤 |
-
2005
- 2005-06-21 EP EP05753416A patent/EP1762234A4/en not_active Withdrawn
- 2005-06-21 WO PCT/JP2005/011371 patent/WO2006001278A1/ja not_active Application Discontinuation
- 2005-06-21 US US11/629,486 patent/US20070244202A1/en not_active Abandoned
-
2011
- 2011-09-06 US US13/226,016 patent/US20110319497A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001072583A (ja) * | 1999-09-07 | 2001-03-21 | Sunstar Inc | 高脂血症の予防又は治療用組成物 |
WO2003009838A1 (fr) * | 2001-07-26 | 2003-02-06 | Institute Of Radiation Medicine, Academy Of Military Medical Sciences, Pla | Utilisation de composes de stilbene dans la preparation de medicaments pour le traitement ou la prevention du diabete et des maladies associees au retrovirus |
WO2003039535A1 (en) * | 2001-10-05 | 2003-05-15 | Interhealth Nutraceuticals, Inc. | Method and composition for preventing or reducing the symptoms of insulin resistance syndrome |
JP2003300904A (ja) * | 2002-04-05 | 2003-10-21 | National Cardiovascular Center | 循環器系障害の進展を抑制する医薬組成物 |
WO2005065667A2 (en) * | 2003-12-29 | 2005-07-21 | President And Fellows Of Harvard College | Compositions for treating or preventing obesity and insulin resistance disorders |
Non-Patent Citations (1)
Title |
---|
See also references of EP1762234A4 * |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5571897B2 (ja) * | 2006-02-14 | 2014-08-13 | 株式会社ファンケル | ビタミンcトランスポーター産生促進剤 |
JP2009533331A (ja) * | 2006-03-31 | 2009-09-17 | ディーエスエム アイピー アセッツ ビー.ブイ. | 身体的外観を改善するための化合物および化合物の組み合わせの新規の使用 |
US20160367497A1 (en) * | 2007-01-26 | 2016-12-22 | Washington University | Methods and compositions for treating neuropathies |
US20140011890A1 (en) * | 2007-01-26 | 2014-01-09 | Washington University | Methods and compositions for treating neuropathies |
US8226991B2 (en) | 2007-09-06 | 2012-07-24 | Fujifilm Corporation | Foodstuff comprising an extract of a plant of the genus Salacia and flavonoid |
JP2013027403A (ja) * | 2007-09-06 | 2013-02-07 | Fujifilm Corp | サラシア属植物の抽出物とフラボノイドを含有する食品 |
JP2009077696A (ja) * | 2007-09-06 | 2009-04-16 | Fujifilm Corp | サラシア属植物の抽出物とフラボノイドを含有する食品 |
JP2011132151A (ja) * | 2009-12-22 | 2011-07-07 | Kirin Holdings Co Ltd | 脂質代謝改善用組成物 |
WO2012072670A2 (en) | 2010-12-03 | 2012-06-07 | L'oreal | Use of a slimming combination |
JP2014028776A (ja) * | 2012-07-31 | 2014-02-13 | Uha Mikakuto Co Ltd | PGC−1α発現促進剤、抗肥満剤及びメタボリックシンドローム予防・治療剤 |
JP2014101341A (ja) * | 2012-11-22 | 2014-06-05 | Uha Mikakuto Co Ltd | 循環器系疾患の予防・治療に対する新規レスベラトロール2量体の利用 |
JP2014125464A (ja) * | 2012-12-27 | 2014-07-07 | Uha Mikakuto Co Ltd | 循環器系疾患の予防・治療効果を有するヒドロキシスチルベン類・シナピン酸反応生成物 |
JP2016513734A (ja) * | 2013-03-15 | 2016-05-16 | エーエルエス マウンテン リミテッド ライアビリティ カンパニー | Ampk活性化剤及びセロトニン作動薬を含む医薬組成物並びにそれらの使用方法 |
JP2013224326A (ja) * | 2013-07-24 | 2013-10-31 | Maruzen Pharmaceut Co Ltd | 肥満解消剤、脂肪分解促進剤、サイクリックamp−ホスホジエステラーゼ活性阻害剤、及びラット副睾丸脂肪細胞の脂肪分解促進剤 |
JP2016042813A (ja) * | 2014-08-21 | 2016-04-04 | ポッカサッポロフード&ビバレッジ株式会社 | 非炭酸飲料、及びその製造方法、並びに非炭酸飲料におけるレトロネイザルアロマの組成の変化抑制方法 |
WO2018002215A1 (en) | 2016-06-30 | 2018-01-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of cardiomyopathies |
WO2020201263A1 (en) | 2019-04-01 | 2020-10-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment and prevention of cardiac remodeling |
Also Published As
Publication number | Publication date |
---|---|
US20110319497A1 (en) | 2011-12-29 |
EP1762234A1 (en) | 2007-03-14 |
US20070244202A1 (en) | 2007-10-18 |
EP1762234A4 (en) | 2010-05-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006001278A1 (ja) | Ampk活性化剤 | |
JP2006273834A (ja) | Ampk活性化剤 | |
JP6619882B2 (ja) | D−プシコースを利用した脂質の吸収抑制および/または排出促進方法 | |
JP6684966B2 (ja) | 新規なラクトバチルス・サケイ及びそれを含む組成物 | |
EP2409696B1 (en) | Agent for promoting energy consumption | |
WO2005074962A1 (ja) | 筋張力増強剤 | |
CN1913911A (zh) | 功能性饮料及组合物 | |
CN108697685A (zh) | 含有桑辛素、桑黄铜g或桑白皮的,肌肉疾病的预防及治疗用或肌功能改善用组合物 | |
KR20150101458A (ko) | 육체적 활동을 증진시키기 위한 상승적 식이 보조제 | |
JP7007663B2 (ja) | クロモジ抽出物 | |
JP2022169385A (ja) | タモギタケ又はその処理物を有効成分として含む、脂質代謝改善剤 | |
JP5804391B2 (ja) | 抗糖化剤 | |
JP2022171876A (ja) | 血糖値上昇抑制用青汁、抗酸化用青汁、整腸用青汁、コラーゲン吸収促進用青汁、カルシウム吸収促進用青汁及び血中コレステロール上昇抑制用青汁 | |
JP7344661B2 (ja) | 食品組成物の製造方法 | |
TW200823219A (en) | ACAT inhibitor | |
JP2009274961A (ja) | 吸収促進剤 | |
JPH11246427A (ja) | 糖・脂質代謝活性化剤 | |
KR101393607B1 (ko) | 미강 발효물을 유효성분으로 함유하는 비알코올성 지방간 예방 및 치료용 조성물 | |
US20220330595A1 (en) | Angiotensin-converting enzyme inhibitor, blood pressure-lowering agent, and beverages and food products | |
JP2007063241A (ja) | Ampk活性化剤 | |
JP2009001507A (ja) | 体脂肪減少剤およびその利用 | |
JP5774839B2 (ja) | 動脈硬化組織内マクロファージ泡沫化抑制剤 | |
WO2024128298A1 (ja) | 持久力向上用及び身体的疲労軽減用の少なくとも一方である剤 | |
WO2023119368A1 (ja) | 液体組成物およびサーチュイン活性化用組成物 | |
JP5706142B2 (ja) | フユボダイジュ花のエタノール抽出物を有効成分とする血中グルコース低下剤、内臓脂肪蓄積抑制剤、tg低下剤、糞中脂肪排泄促進剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REEP | Request for entry into the european phase |
Ref document number: 2005753416 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005753416 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11629486 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 2005753416 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11629486 Country of ref document: US |